These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 10231151)

  • 1. Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantation.
    Abecasis MM; Conceição Silva JP; Ferreira I; Guimarães A; Machado A
    Bone Marrow Transplant; 1999 Apr; 23(8):843-6. PubMed ID: 10231151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF).
    Kaleelrahman M; Eaton JD; Leeming D; Bowyer K; Taberner D; Chang J; Scarffe JH; Chopra R
    Hematology; 2003 Apr; 8(2):91-5. PubMed ID: 12745658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide.
    Jenner MJ; Micallef IN; Rohatiner AZ; Kelsey SM; Newland AC; Cavenagh JD
    Med Oncol; 2000 Nov; 17(4):333-6. PubMed ID: 11114714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease.
    Palladino M; Miele L; Pompili M; Forgione A; Vellone V; Vecchio FM; Chiusolo P; Laurenti L; Gasbarrini G; Sica S; Grieco A
    Clin Transplant; 2008; 22(6):837-41. PubMed ID: 18713263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment with defibrotide for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation.
    Yakushijin K; Matsui T; Okamura A; Yamamoto K; Ito M; Chihara K
    Kobe J Med Sci; 2005; 51(3-4):55-65. PubMed ID: 16444097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
    Corbacioglu S; Kernan N; Lehmann L; Brochstein J; Revta C; Grupp S; Martin P; Richardson PG
    Expert Rev Hematol; 2012 Jun; 5(3):291-302. PubMed ID: 22780209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment.
    Lee JH; Lee KH; Choi JS; Zang DY; Kim SB; Kim SW; Suh C; Lee JS; Kim WK; Lee YS; Kim SH
    J Korean Med Sci; 1996 Apr; 11(2):118-26. PubMed ID: 8835758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double treatment of severe hepatic veno-occlusive disease after allogeneic peripheral blood progenitor cell transplantation with recombinant tissue plasminogen activator.
    Söhngen D; Bauser U; Boogen C; Aul C; Frieling T; Germing U; Schneider P; Kobbe G; Heyll A
    Thromb Haemost; 1997 Oct; 78(4):1299-300. PubMed ID: 9365005
    [No Abstract]   [Full Text] [Related]  

  • 9. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
    Qureshi A; Marshall L; Lancaster D
    Pediatr Blood Cancer; 2008 Apr; 50(4):831-2. PubMed ID: 18286502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.
    Richardson PG; Elias AD; Krishnan A; Wheeler C; Nath R; Hoppensteadt D; Kinchla NM; Neuberg D; Waller EK; Antin JH; Soiffer R; Vredenburgh J; Lill M; Woolfrey AE; Bearman SI; Iacobelli M; Fareed J; Guinan EC
    Blood; 1998 Aug; 92(3):737-44. PubMed ID: 9680339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of veno-occlusive disease with recombinant tissue plasminogen activator in a patient requiring peritoneal dialysis.
    Simpson DR; Browett PJ; Doak PB; Palmer SJ
    Bone Marrow Transplant; 1994 Oct; 14(4):635-6. PubMed ID: 7858540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.
    Richardson PG; Murakami C; Jin Z; Warren D; Momtaz P; Hoppensteadt D; Elias AD; Antin JH; Soiffer R; Spitzer T; Avigan D; Bearman SI; Martin PL; Kurtzberg J; Vredenburgh J; Chen AR; Arai S; Vogelsang G; McDonald GB; Guinan EC
    Blood; 2002 Dec; 100(13):4337-43. PubMed ID: 12393437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies.
    Ho VT; Revta C; Richardson PG
    Bone Marrow Transplant; 2008 Feb; 41(3):229-37. PubMed ID: 17994121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of tissue plasminogen activator in the treatment of veno-occlusive liver disease after bone marrow transplantation.
    Terra SG; Spitzer TR; Tsunoda SM
    Pharmacotherapy; 1997; 17(5):929-37. PubMed ID: 9324182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study.
    Chopra R; Eaton JD; Grassi A; Potter M; Shaw B; Salat C; Neumeister P; Finazzi G; Iacobelli M; Bowyer K; Prentice HG; Barbui T
    Br J Haematol; 2000 Dec; 111(4):1122-9. PubMed ID: 11167751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA).
    Baglin TP; Harper P; Marcus RE
    Bone Marrow Transplant; 1990 Jun; 5(6):439-41. PubMed ID: 2369685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late-onset hepatic veno-occlusive disease post autologous peripheral stem cell transplantation successfully treated with oral defibrotide.
    Shah MS; Jeevangi NK; Joshi A; Khattry N
    J Cancer Res Ther; 2009; 5(4):312-4. PubMed ID: 20160371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation.
    Hägglund H; Ringdén O; Ljungman P; Winiarski J; Ericzon B; Tydén G
    Transplant Proc; 1995 Dec; 27(6):3535. PubMed ID: 8540088
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: impact on coagulation profile.
    Goldberg SL; Shubert J; Rao AK; Redei I; Klumpp TR; Mangan KF
    Bone Marrow Transplant; 1996 Sep; 18(3):633-6. PubMed ID: 8879629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.
    Corbacioglu S; Cesaro S; Faraci M; Valteau-Couanet D; Gruhn B; Rovelli A; Boelens JJ; Hewitt A; Schrum J; Schulz AS; Müller I; Stein J; Wynn R; Greil J; Sykora KW; Matthes-Martin S; Führer M; O'Meara A; Toporski J; Sedlacek P; Schlegel PG; Ehlert K; Fasth A; Winiarski J; Arvidson J; Mauz-Körholz C; Ozsahin H; Schrauder A; Bader P; Massaro J; D'Agostino R; Hoyle M; Iacobelli M; Debatin KM; Peters C; Dini G
    Lancet; 2012 Apr; 379(9823):1301-9. PubMed ID: 22364685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.